Vanguard Group Inc Moon Lake Immunotherapeutics Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Vanguard Group Inc holds 120,869 shares of MLTX stock, worth $6.69 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
120,869
Previous 114,018
6.01%
Holding current value
$6.69 Million
Previous $4.45 Million
28.09%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding MLTX
# of Institutions
160Shares Held
55.1MCall Options Held
451KPut Options Held
199K-
Bvf Inc San Francisco, CA19.8MShares$1.09 Billion33.91% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$470 Million35.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.97MShares$165 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$153 Million1.75% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.48MShares$81.9 Million0.01% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $2.04B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...